Breast Cancer Aotearoa Coalition and Breast Cancer Foundation NZ have made a strongly worded and evidence-based joint submission to PHARMAC requesting that funding for Perjeta (pertuzumab) be extended to all people with HER2-positive advanced breast cancer.
Representatives of Breast Cancer Aotearoa Coalition (BCAC) went to Wellington recently to meet with Government and National MPs who have health responsibilities to discuss some of the key issues affecting those with breast cancer.
The two key issues highlighted by BCAC in the talks were the need to improve access to medicines; and the need to address inequities for Māori and Pasifika women in breast cancer screening and treatment.
Important research released 21 June shows huge disparities in breast cancer screening, treatment and outcomes for Māori and Pasifika women in New Zealand.
The Breast Cancer Aotearoa Coalition (BCAC) says this is unacceptable and is calling for significant immediate steps to be taken to improve this situation.
BCAC is thrilled a clinical trial involving American engineer Judy Perkins has led to her being declared free of breast cancer with what specialists are calling an extended remission. This wonderful news has come two years after she was told she had only three months to live.
More women with the most common form of early stage breast cancer may not need chemotherapy and may instead rely on hormone therapies, according to a landmark study.
The findings in the study were based on a 21-tumor gene expression test which would also inform treatment decisions in real life.
American researchers have hopes a new blood test they have developed may in the future be able to detect 10 types of cancer potentially years before someone becomes unwell.
Recent research has found that changing to a low-fat diet may have a positive influence on breast cancer outcomes.
A study led by Dr Rowan T Chlebowski, PhD of the City of Hope National Medical Center in California found that, in a randomized clinical trial, a low-fat eating pattern was associated with lower risk of death after breast cancer.
BCAC says a new report highlights how desperately poor access to new and innovative medicines is in New Zealand.
The Medicines NZ Medicines Landscape 2017 report finds that New Zealand comes last out of 20 comparable OECD countries for access to publicly-funded new medicines.
The report says this means more than 230,000 patients in New Zealand are currently waiting for access to medicines that are not yet approved for public funding in this country.
BCAC committee member, Louise Malone, attended the San Antonio Breast Cancer Symposium in December 2017 and gives us an update on the latest cutting-edge research into new targeted immunotherapy treatments.
As cancer researchers better understand the complex interchanges between tumour cells and immune cells and the microenvironment in which they operate, new targets for therapy are emerging.
Many charities rely on the time and expertise of volunteers to provide their services. Finding people with enough of both can be a challenge.
BCAC member group, Breast Cancer Support (BCS) has risen to that challenge, appointing a new governing team of seven multi-talented, enthusiastic and motivated women at its recent AGM.
